Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study

Pathology International

Volumn 50, Issue 7, 2000, Pages 527-530

  Umekita, Yoshihisa ^a   Yoshida, Hiroki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Atypical ductal hyperplasia; Cyclin D1; Ductal carcinoma in situ

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DUCT; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CARCINOMA IN SITU; CELL CYCLE G1 PHASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CYCLIN D1; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033863603     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2000.01076.x     Document Type: Article

References (27)

1. 1 Sherr CJ. D-type cyclins. Trends Biol. Sci. 1995; 20: 187-190.
2. 2 Gillett C, Smith P, Gregory W et al. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer (Pred. Oncol.) 1996; 69: 92-99.
3. 3 Jares P, Rey MJ, Fernandez PL et al. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: Correlation with tumor proliferation and oestrogen receptor status. J. Pathol. 1997; 182: 160-166.
4. 4 Michalides R, Hageman P, van Tinteren H et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer 1996; 73: 728-734.
5. 5 van Diest PJ, Michalides RJAM, Jannink I et al. Cyclin D1 expression in invasive breast cancer: Correlations and prognostic value. Am. J. Pathol. 1997; 150: 705-711.
6. 6 Zukerberg LR, Yang WI, Gadd M et al. Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show over-expression of the cyclin D1 oncogene. Mod. Pathol. 1995; 8: 560-567.
7. 7 Alle KK, Henshall SM, Field AS, Sutherland RL. Cyclin D 1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin. Cancer Res. 1998; 4: 847-854.
8. 8 Gillett CE, Lee AHS, Millis RP, Barnes DM. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J. Pathol. 1998; 184: 396-400.
9. 9 Simpson JF, Quan DE, Ornalley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, Cyclin D1, in ductal carcinoma in situ of the breast. Am. J. Pathol. 1997; 151: 161-168.
10. 10 Vos CBJ, Ter Haar NT, Peterse JL, Cornelisse CJ, Van De Vijver MJ. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J. Pathol. 1999; 187: 279-284.
11. 11 Zhu XL, Hartwick W, Rohan T, Kandel R. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Mod. Pathol. 1998; 11: 1082-1088.
12. 12 Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol. 1992; 23: 1095-1097.
13. 13 Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J. Pathol. 1999; 187: 272-278.
14. 14 Steeg PS, Clare SE, Lawrence JA, Zhou Q. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am. J. Pathol. 1996; 149: 733-738.
15. 15 World Health Organization. Histological Typing of Breast Tumours, 2nd edn. WHO, Geneva, 1981.
16. 16 Umekita Y, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, noninvasive and invasive mammary carcinoma: an immunohistochemical study. Virchows Arch. 1994; 424: 491-494.
17. 17 Bartek J, Bartkova J, Vojtesek B et al. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int. J. Cancer 1990; 46: 839-844.
18. 18 Schmitt FC, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J. Pathol. 1995; 176: 233-241.
19. 19 Lodato R, Maguire H, Greene M, Weiner D, LiVolsi V. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod. Pathol. 1990; 3: 449-454.
20. 20 Gusterson BA, Machin LG, Gullick WJ et al. c-erbB-2 expression in benign and malignant breast disease. Br. J. Cancer 1988; 58: 453-457.
21. 21 Holland R, Peterse JL, Millis RR et al. Ductal carcinoma in situ: A proposal for a new classification. Semin. Diagn. Pathol. 1994; 11: 167-180.
22. 22 Poller DN, Roberts EC, Bell JA et al. p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum. Pathol. 1993; 24: 463-468.
23. 23 Scott MA, Lagios MID, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum. Pathol. 1997; 28: 967-973.
24. 24 Hendricks JB, Wilkinson EJ. Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumors. Mod. Pathol. 1993; 6: 765-770.
25. 25 Fantle V, Richards MA, Smith R et al. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur. J. Cancer 1990; 26: 423-424.
26. 26 Weinstat-Saslow P, Merino MJ, Manrow RE et al. Overexpression of cyclin D mRNA distinguishes and in situ breast carcinomas from non-malignant lesions. Nature Med. 1995; 12: 1257-1260.
27. 27 Mommers ECM, van Diest PJ, Leonhart AM, Meijer CJLK, Baak JPA. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum. Pathol. 1998; 29: 1539-1545.